Charles River Laboratories International Future Growth
Future criteria checks 1/6
Charles River Laboratories International is forecast to grow earnings and revenue by 11.4% and 5.4% per annum respectively. EPS is expected to grow by 11.4% per annum. Return on equity is forecast to be 13.9% in 3 years.
Key information
11.4%
Earnings growth rate
11.4%
EPS growth rate
| Life Sciences earnings growth | 15.9% |
| Revenue growth rate | 5.4% |
| Future return on equity | 13.9% |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance
Nov 02Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds
Oct 18Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?
Oct 18Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Oct 04Charles River raised to Buy at Jefferies on prospects for animal studies
Sep 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,912 | 629 | 648 | 990 | 9 |
| 12/31/2025 | 4,543 | 525 | 571 | 886 | 15 |
| 12/31/2024 | 4,223 | 420 | 455 | 753 | 15 |
| 12/30/2023 | 4,129 | 475 | 365 | 684 | N/A |
| 9/30/2023 | 4,216 | 475 | 368 | 698 | N/A |
| 7/1/2023 | 4,178 | 484 | 289 | 625 | N/A |
| 4/1/2023 | 4,092 | 496 | 275 | 626 | N/A |
| 12/31/2022 | 3,976 | 486 | 295 | 620 | N/A |
| 9/24/2022 | 3,781 | 436 | 280 | 614 | N/A |
| 6/25/2022 | 3,688 | 443 | 338 | 656 | N/A |
| 3/26/2022 | 3,630 | 422 | 412 | 693 | N/A |
| 12/25/2021 | 3,540 | 391 | 532 | 761 | N/A |
| 9/25/2021 | 3,426 | 397 | 452 | 670 | N/A |
| 6/26/2021 | 3,273 | 396 | 484 | 672 | N/A |
| 3/27/2021 | 3,041 | 375 | 479 | 648 | N/A |
| 12/26/2020 | 2,924 | 364 | 380 | 547 | N/A |
| 9/26/2020 | 2,824 | 301 | 446 | 589 | N/A |
| 6/27/2020 | 2,749 | 271 | 416 | 567 | N/A |
| 3/28/2020 | 2,724 | 248 | 385 | 535 | N/A |
| 12/28/2019 | 2,621 | 252 | 340 | 481 | N/A |
| 9/28/2019 | 2,532 | 231 | 295 | 440 | N/A |
| 6/29/2019 | 2,449 | 219 | 269 | 402 | N/A |
| 3/30/2019 | 2,377 | 227 | 264 | 393 | N/A |
| 12/29/2018 | 2,266 | 225 | 297 | 437 | N/A |
| 9/29/2018 | 2,143 | 135 | 321 | 421 | N/A |
| 6/30/2018 | 2,022 | 128 | 264 | 363 | N/A |
| 3/31/2018 | 1,906 | 129 | 248 | 342 | N/A |
| 12/30/2017 | 1,858 | 123 | 234 | 316 | N/A |
| 9/30/2017 | 1,846 | 198 | N/A | 310 | N/A |
| 7/1/2017 | 1,807 | 183 | N/A | 323 | N/A |
| 4/1/2017 | 1,772 | 164 | N/A | 303 | N/A |
| 12/31/2016 | 1,681 | 154 | N/A | 315 | N/A |
| 9/24/2016 | 1,568 | 143 | N/A | 299 | N/A |
| 6/25/2016 | 1,492 | 143 | N/A | 315 | N/A |
| 3/26/2016 | 1,398 | 156 | N/A | 321 | N/A |
| 12/26/2015 | 1,363 | 150 | N/A | 305 | N/A |
| 9/26/2015 | 1,339 | 146 | N/A | 284 | N/A |
| 6/27/2015 | 1,317 | 140 | N/A | 263 | N/A |
| 3/28/2015 | 1,319 | 127 | N/A | 234 | N/A |
| 12/27/2014 | 1,298 | 128 | N/A | 251 | N/A |
| 9/27/2014 | 1,257 | 120 | N/A | 214 | N/A |
| 6/28/2014 | 1,222 | 119 | N/A | 214 | N/A |
| 3/29/2014 | 1,174 | 111 | N/A | 205 | N/A |
| 12/28/2013 | 1,166 | 104 | N/A | 207 | N/A |
| 9/28/2013 | 1,156 | 108 | N/A | 210 | N/A |
| 6/29/2013 | 1,143 | 99 | N/A | 203 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRL's forecast earnings growth (11.4% per year) is above the savings rate (2.3%).
Earnings vs Market: CRL's earnings (11.4% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: CRL's earnings are forecast to grow, but not significantly.
Revenue vs Market: CRL's revenue (5.4% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: CRL's revenue (5.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CRL's Return on Equity is forecast to be low in 3 years time (13.9%).